YAP1 and ovarian serous adenocarcinoma: Finally, we collected baseline platelet counts from 358 stage III and IV high-grade serous ovarian cancer patients whose gene expression patterns were previously analyzed by The Cancer Genome Atlas Research Network23 and applied a verified gene signature for YAP1 activation, which was shown to significantly correlate with patient survival24, 25.